Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Shares Issued (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed Shares Issued for 7 consecutive years, with $19.2 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Issued rose 3487.66% year-over-year to $19.2 million; the TTM value through Mar 2026 reached $81.6 million, up 137.43%, while the annual FY2025 figure was $61.6 million, 26.43% up from the prior year.
  • Shares Issued hit $19.2 million in Q1 2026 for Kymera Therapeutics, down from $46.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $46.7 million in Q4 2025 and bottomed at -$193000.0 in Q2 2022.
  • Average Shares Issued over 5 years is $9.8 million, with a median of $3.5 million recorded in 2023.
  • Year-over-year, Shares Issued plummeted 104.66% in 2022 and then surged 4368.29% in 2023.
  • Kymera Therapeutics' Shares Issued stood at -$82000.0 in 2022, then soared by 4368.29% to $3.5 million in 2023, then soared by 518.29% to $21.6 million in 2024, then skyrocketed by 115.9% to $46.7 million in 2025, then tumbled by 58.92% to $19.2 million in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $19.2 million, $46.7 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.